



3R MATRIX

	+	=	-
Right Sector (RS)	✓	✗	✗
Right Quality (RQ)	✓	✗	✗
Right Valuation (RV)	✓	✗	✗

+ Positive = Neutral - Negative

What has changed in 3R MATRIX

	Old		New
RS	✓	↔	✓
RQ	✓	↔	✓
RV	✓	↔	✓


Company details

Market cap:	Rs. 1,19,370 cr
52-week high/low:	Rs. 1702/1165
NSE volume: (No of shares)	34.75 lakh
BSE code:	500087
NSE code:	CIPLA
Free float: (No of shares)	55.7 cr

Shareholding (%)

Promoters	30.9
FII	28.8
DII	24.0
Others	16.3

Price chart



Price performance

(%)	1m	3m	6m	12m
Absolute	-2.7	1.5	12.1	32.2
Relative to Sensex	-24.5	-18.8	-24.3	-5.2

Sharekhan Research, Bloomberg

Cipla Ltd

Meaningful new launches to drive growth

Pharmaceuticals

Sharekhan code: CIPLA

Reco/View: Buy



Upgrade



Maintain



Downgrade

CMP: Rs. 1,477

Price Target: Rs. 1,715



Summary

- Cipla's revenue reached Rs. 7,051 crore, reflecting a 7% y-o-y increase and a 6% q-o-q rise, meeting our expectations.
- EBITDA stood at Rs. 1,886 crore with 15% y-o-y growth; it slightly missed our estimates by 1% and margins remained steady at 27%.
- Cipla is poised for growth in North America, driven by demand for its generic asthma drug and cancer injectables, along with four new approvals secured during the quarter.
- Cipla has planned meaningful peptide launches in FY2025E and domestic growth from its strong product portfolio. We maintain BUY with a revised PT of Rs. 1,715, as the stock trades at 22x and 19x its estimated FY2026 and FY2027 EPS of Rs. 66.95 and Rs. 77.98.

Cipla's revenue reached Rs. 7,051 crore, representing a 7% y-o-y and a 6% q-o-q increase, which aligns well with our expectations. The company's EBITDA stood at Rs. 1,886 crore, showing a strong 15% y-o-y, although it was slightly below our estimates by 1%. Margins remained stable at 27%, perfectly matching our projections. As anticipated, Cipla experienced slower profit growth, mainly due to seasonal fluctuations in both the Indian and U.S. markets. However, there is a positive aspect to consider: the reduction in material costs is expected to bolster EBITDA and margins moving forward. Looking ahead, Cipla is strategically positioned for growth in the North American market, driven by increasing demand for its generic asthma medication and cancer injectables. Moreover, the company secured four regulatory approvals during the quarter, further strengthening its growth potential in this region.

Key positives

- Four new drug approvals during the quarter.
- Ranked #2 in the overall South African private market.
- The company successfully implemented the change in distribution model with business coming closer to the channel.

Management Commentary

- EBITDA guidance remains steady at 24.5–25.5%.
- No sales guidance is provided for Lanreotide due to the contract with the partner.
- The guidance for gSymbicort, gQvar, and another inhaled partner asset remains unchanged.
- In South Africa, the emphasis is on expanding margins.

Revision in Estimates - Earnings estimates for FY2025 and FY2026 have been slightly adjusted, and FY2027 estimates have been introduced based on the company's recent guidance.

Our Call

View – Maintain BUY with a revised PT of Rs. 1,715: Cipla has posted a good set of earnings driven by 1) Meaningful Revlimid contribution, increased market share in key products like Albuterol and Lanreotide followed by easing of price erosion to 4–6% resulting into the highest-ever quarterly sales run rate of USD250 million, 2) Higher chronic-based growth in the domestic region, and 3) OTC-led growth in the South Africa region. A healthy product mix resulted in a higher EBITDA margin. Going forward, we expect the North American region to maintain its growth momentum, led by 1) meaningful new launches including peptides and complex respiratory drugs, followed by the launch of gSymbicort and two-player market drug gAdvair, 2) An increase in the market share of Albuterol and Leuprolide as no competitors are expected, 3) Increase in the market share of Lanreotide 505b2, 4) Launch of another peptide product in FY2025E and remaining three peptide by FY2026E. We believe a healthy product mix would increase the EBITDA margin to 26% by FY2026E. The stock is trading at an attractive P/E valuation of 22x/19x its FY2026E/FY2027E EPS of Rs. 66.95/Rs. 77.98 per share. Hence, we maintain BUY rating with a revised price target (PT) of Rs. 1,715.

Key Risks

1) Currency fluctuations, 2) Delay in key product approvals/faster approvals for competitors' products, and 3) Any regulatory changes in India, South Africa, or the U.S. could affect the business.

Valuation (Consolidated)

Particulars	FY23	FY24	FY25E	FY26E	FY27E
Sales	22753	25774	27836	30341	33375
EBITDA	5027	6291	6959	7737	8678
EBITDAM (%)	22%	24%	25%	26%	26%
PAT	2802	4122	4454	5158	6008
NPM (%)	12%	16%	16%	17%	18%
EPS (Rs.)	37.00	53.50	57.81	66.95	77.98
P/E	40x	28x	26x	22x	19x
P/BV	5x	5x	4x	4x	3x
EV/EBITDA	22x	20x	19x	17x	15x
ROE (%)	13%	16%	16%	15%	15%
ROCE (%)	17%	19%	19%	20%	20%

Source: Company; Sharekhan estimates

Q2FY2025 Con Call Highlights

- ◆ The mix benefit from tender businesses has had a positive effect on gross margins.
- ◆ The company anticipates a normalised performance in the third and fourth quarters, with the fourth quarter typically exhibiting margins below 20%.
- ◆ The company secured four new generic drug approvals in the U.S. market, including one peptide.
- ◆ The company aims to obtain approval in China in the future.
- ◆ Albuterol's market share rose to 19% this quarter, although competition in the market is causing some erosion.
- ◆ The company's vintage portfolio of oral solids, which makes up 30% of its offerings, is facing erosion due to competitive pressures.
- ◆ The Lanreotide franchise, including 505B2 and ANDA assets, achieved a market share of 35% this quarter, according to IQVIA data from March 2024.
- ◆ The company is currently experiencing temporary supply issues with Lanreotide, which are expected to affect sales in the third quarter, but these issues should be resolved by the end of that quarter.
- ◆ The company is exploring new areas, such as oligonucleotides and peptides, and is nearly finished with its full portfolio.
- ◆ The company is working to enhance the overall capacity of Lanreotide through a capex investment from its partner.
- ◆ The company plans to pursue acquisitions in India within the DOM formulation space, followed by potential opportunities in the U.S.
- ◆ The company has seen erosion in areas where they hold government supply agreements.
- ◆ The launch of the significant inhalation asset, generic Advair, is expected in the first half of FY2026.

Results

Particulars	Rs cr				
	Q2FY25	Q2FY24	YoY (%)	Q1FY25	QoQ (%)
Revenue	7,051	6,678	6%	6,694	5%
Total Expenditure	5,165	4,944	4%	4,978	4%
Operating profit	1886	1734	9%	1716	10%
Other Income	191	176	8%	160.19	19%
Interest	15	26	-40%	17.95	-14%
Depreciation	272	290	-6%	246.68	10%
PBT	1,789	1,594	12%	1,611	11%
Tax	483	438	10%	435.07	11%
Adjusted PAT	1,306	1,156	13%	1,176	11%
EPS (Rs.)	16.13	14.01	-	14.58	-
Margins (%)			BPS		BPS
OPM	27%	26%	78bps	26%	111bps
NPM	19%	17%	122bps	18%	95bps
Tax rate	27%	28%	-50bps	27%	0bps

Source: Company, Sharekhan Research

Outlook and Valuation

■ Sector view - Input cost easing with companies focusing on complex product launches

Over the years, Indian pharmaceutical companies have established themselves as a dependable source for global pharma companies. The confluence of other factors, including a focus on specialty/complex products in addition to emerging opportunities in the API space, would be key growth drivers over the long term. The sector is witnessing the easing of input costs like raw-material cost, freight cost, and power cost, which aid the sector in expanding margins. The sector is also witnessing the easing of price erosion followed by increasing contributions from new product launches. We believe the sector is in a sweet spot, where it is experiencing a healthy product mix and cost rationalisation, which increases operational profit of the companies. The sector is mainly a low-debt sector, witnessing increasing operational profit followed by the advantage of a low tax rate due to its operations in the SEZ sector; hence, overall, we have a positive view on the sector.

■ Company outlook - Long-term outlook is strong

Cipla has seen an increase in the U.S. revenue base to USD222 million a quarter versus an average base of USD160 million before, driven by differentiated products. The company's differentiated products comprising respiratory and peptide products are performing well in the U.S. Although some of the concerns are that gAbraxane's and gAdvair's launches are likely to be delayed due to USFDA compliance pending at Indore and Goa plants, they are being de-risked. At the same time, India market growth is recovering and expected to continue to grow on account of a strong set of product launches in branded prescription and trade generics. A rebalanced supply chain in the U.S. coupled with a strong set of existing products such as gRevlimid and Lanreotide should continue to drive profitable growth over FY2023-FY2025E.

■ Valuation - Maintain BUY with a revised PT of Rs. 1,715

Cipla has posted a good set of earnings driven by 1) Meaningful Revlimid contribution, increased market share in key products like Albuterol and Lanreotide followed by easing of price erosion to 4-6% resulting into the highest-ever quarterly sales run rate of USD250 million, 2) Higher chronic-based growth in the domestic region, and 3) OTC-led growth in the South Africa region. A healthy product mix resulted in a higher EBITDA margin. Going forward, we expect the North American region to maintain its growth momentum, led by 1) meaningful new launches including peptides and complex respiratory drugs, followed by the launch of gSymbicort and two-player market drug gAdvair, 2) An increase in the market share of Albuterol and Leuprolide as no competitors are expected, 3) Increase in the market share of Lanreotide 505b2, 4) Launch of another peptide product in FY2025E and remaining three peptide by FY2026E. We believe a healthy product mix would increase the EBITDA margin to 26% by FY2026E. The stock is trading at an attractive P/E valuation of 22x/19x its FY2026E/FY2027E EPS of Rs. 66.95/Rs. 77.98 per share. Hence, we maintain BUY rating with a revised PT of Rs. 1,715.

About company

Cipla is a global pharmaceutical company with a geographically diversified presence and products registered in more than 170 countries. Indian branded formulations account for more than 40% of business and Cipla is among the top three players in the market. In the past, the company believed in the partnership model for international markets. However, in the past three years, the company has been undergoing a strategic shift and has started setting up its front-end divisions. Cipla is also a well-known global player in inhalers and antiretrovirals. Going forward, the company plans to launch combination inhalers in larger markets such as the U.S. and EU and is setting up its front ends to drive growth

Investment theme

Cipla banks on its branded business in India and South Africa, both of which together contribute ~56% to the business. A solid presence in the chronic segment in domestic markets along with a market leadership position in select chronic therapies such as respiratory, inhalation, and urology bodes well for the company. The recently launched complex and differentiated products have done extremely well in the U.S. Additionally, the India market would recover its sales growth post the high base effect from COVID-19 wanes away. At the same time, SAGA is recovering with market-beating growth. Although its key launches stand pending due to USFDA facility clearances, they are being de-risked with launches likely over the next two years.

Key Risks

- ♦ Currency fluctuations could have an adverse impact.
- ♦ Any delay in key product approvals/faster approvals for competitors.
- ♦ Any regulatory changes in India or South Africa or the U.S. could affect business.

Additional Data

Key management personnel

Umang Vohra	MD/CEO
Dr. Pradeep Bhaduria	Chief Scientific Officer
Ashish Adukia	Chief Financial Officer

Source: Company

Top 10 shareholders

Sr. No.	Holder Name	Holding (%)
1	HDFC Asset Management Co Ltd.	5.69
2	Blackrock Inc.	5.1
3	Life Insurance Corp of India	3.12
4	SBI Funds Management Ltd.	2.74
5	The Vanguard Group Inc.	2.69
6	Norges Bank	2.03
7	NPS Trust A/c Uti Retirement Solution	1.4
8	ICICI Prudential AMC	1.11
9	UTI Asset Management Co. Ltd.	1.04
10	Kotak Mahindra Asset Management Co.	1.03

Source: Bloomberg

Sharekhan Limited, its analyst or dependant(s) of the analyst might be holding or having a position in the companies mentioned in the article.

Understanding the Sharekhan 3R Matrix

Right Sector	
Positive	Strong industry fundamentals (favorable demand-supply scenario, consistent industry growth), increasing investments, higher entry barrier, and favorable government policies
Neutral	Stagnancy in the industry growth due to macro factors and lower incremental investments by Government/private companies
Negative	Unable to recover from low in the stable economic environment, adverse government policies affecting the business fundamentals and global challenges (currency headwinds and unfavorable policies implemented by global industrial institutions) and any significant increase in commodity prices affecting profitability.
Right Quality	
Positive	Sector leader, Strong management bandwidth, Strong financial track-record, Healthy Balance sheet/cash flows, differentiated product/service portfolio and Good corporate governance.
Neutral	Macro slowdown affecting near term growth profile, Untoward events such as natural calamities resulting in near term uncertainty, Company specific events such as factory shutdown, lack of positive triggers/events in near term, raw material price movement turning unfavourable
Negative	Weakening growth trend led by led by external/internal factors, reshuffling of key management personal, questionable corporate governance, high commodity prices/ weak realisation environment resulting in margin pressure and deteriorating balance sheet
Right Valuation	
Positive	Strong earnings growth expectation and improving return ratios but valuations are trading at discount to industry leaders/historical average multiples, Expansion in valuation multiple due to expected outperformance amongst its peers and Industry up-cycle with conducive business environment.
Neutral	Trading at par to historical valuations and having limited scope of expansion in valuation multiples.
Negative	Trading at premium valuations but earnings outlook are weak; Emergence of roadblocks such as corporate governance issue, adverse government policies and bleak global macro environment etc warranting for lower than historical valuation multiple.

Source: Sharekhan Research

DISCLAIMER

This information/document has been prepared by Sharekhan Ltd. (SHAREKHAN) and is intended for use only by the person or entity to which it is addressed to. This Document may contain confidential and/or privileged material and is not for any type of circulation and any review, retransmission, or any other use is strictly prohibited. This information/ document is subject to changes without prior notice.

Recommendation in reports based on technical and derivatives analysis is based on studying charts of a stock's price movement, trading volume, outstanding positions, as opposed to focusing on a company's fundamentals and as such, may not match with a report on a company's fundamentals. However, this would only apply for information/document focused on technical and derivatives research and shall not apply to reports/documents/information focused on fundamental research.

This information/document does not constitute an offer to sell or solicitation for the purchase or sale of any financial instrument or as an official confirmation of any transaction. Though disseminated to all customers who are due to receive the same, not all customers may receive this report at the same time. SHAREKHAN will not treat recipients as customers by virtue of their receiving this information/report.

The information contained herein is obtained from publicly available data or other sources believed to be reliable and SHAREKHAN has not independently verified the accuracy and completeness of the said data and hence it should not be relied upon as such. While we would endeavour to update the information herein on reasonable basis, SHAREKHAN, its subsidiaries and associated companies, their directors and employees ("SHAREKHAN and affiliates") are under no obligation to update or keep the information current. Also, there may be regulatory, compliance, or other reasons that may prevent SHAREKHAN and affiliates from doing so. This document is prepared for assistance only and is not intended to be and must not alone be taken as the basis for an investment decision. Recipients of this report should also be aware that past performance is not necessarily a guide to future performance and value of investments can go down as well. The user assumes the entire risk of any use made of this information. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved) and should consult its own advisors to determine the merits and risks of such an investment. The investment discussed or views expressed may not be suitable for all investors. We do not undertake to advise you as to any change of our views. Affiliates of Sharekhan may have issued other recommendations/ reports that are inconsistent with and reach different conclusions from the information presented in this recommendations/report.

This information/recommendation/report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject SHAREKHAN and affiliates to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction.

The analyst certifies that the analyst might have dealt or traded directly or indirectly in securities of the company and that all the views expressed in this document accurately reflect his or her personal views about the subject company or companies and its or their securities and do not necessarily reflect those of SHAREKHAN. The analyst and SHAREKHAN further certifies that either he or his relatives or Sharekhan associates might have direct or indirect financial interest or might have actual or beneficial ownership of 1% or more in the securities of the company at the end of the month immediately preceding the date of publication of the research report. The analyst and SHAREKHAN encourages independence in research report/ material preparation and strives to minimize conflict in preparation of research report. The analyst and SHAREKHAN does not have any material conflict of interest or has not served as officer, director or employee or engaged in market making activity of the company. The analyst and SHAREKHAN has not been a part of the team which has managed or co-managed the public offerings of the company, and no part of the analyst's compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this document. Sharekhan Ltd or its associates or analysts have not received any compensation for investment banking, merchant banking, brokerage services or any compensation or other benefits from the subject company or from third party in the past twelve months in connection with the research report.

Either SHAREKHAN or its affiliates or its directors or employees / representatives / clients or their relatives may have position(s), make market, act as principal or engage in transactions of purchase or sell of securities, from time to time or may be materially interested in any of the securities or related securities referred to in this report and they may have used the information set forth herein before publication. SHAREKHAN may from time to time solicit from, or perform investment banking, or other services for, any company mentioned herein. Without limiting any of the foregoing, in no event shall SHAREKHAN, any of its affiliates or any third party involved in, or related to, computing or compiling the information have any liability for any damages of any kind.

Forward-looking statements (if any) are provided to allow potential investors the opportunity to understand management's beliefs and opinions in respect of the future so that they may use such beliefs and opinions as one factor in evaluating an investment. These statements are not a guarantee of future performance and undue reliance should not be placed on them. Such forward-looking statements necessarily involve known and unknown risks and uncertainties, which may cause actual performance and financial results in future periods to differ materially from any projections of future performance or result expressed or implied by such forward-looking statements. Sharekhan/its affiliates undertakes no obligation to update forward-looking statements if circumstances or management's estimates or opinions should change except as required by applicable securities laws. The reader/investors are cautioned not to place undue reliance on forward-looking statements and use their independent judgement before taking any investment decision.

Investment in securities market are subject to market risks, read all the related documents carefully before investing. The securities quoted are for illustration only and are not recommendatory. Registration granted by SEBI, and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Client should read the Risk Disclosure Document issued by SEBI & relevant exchanges and the T&C on www.sharekhan.com

Registration and Contact Details: Name of Research Analyst - Sharekhan Limited, Research Analyst Regn No.: INH000006183. CIN: - U99999MH1995PLC087498.

Registered Office: The Ruby, 18th Floor, 29 Senapati Bapat Marg, Dadar (West), Mumbai – 400 028, Maharashtra, INDIA. Tel: 022-6115000.

Correspondence/Administrative Office Address - Gigaplex IT Park, Unit No 1001, 10th Floor, Building No.9, TTC Industrial Area, Digha, Airoli-West, Navi Mumbai – 400708. Tel: 022 61169000 / 61150000, Fax No. 61169699.

Other registrations of Sharekhan Ltd.: SEBI Regn. Nos.: BSE / NSE (CASH / F&O / CD) / MCX - Commodity: INZ000171337; BSE – 748, NSE – 10733, MCX – 56125, DP: NSDL/CDSL-IN-DP-365-2018; PMS: INP000005786; Mutual Fund: ARN 20669 (date of initial registration: 03/07/2004, and valid till 02/07/2026); IRDAI Registered Corporate Agent (Composite) License No. CA0950, valid till June 13, 2027.

Compliance Officer: Ms. Binkle R. Oza; Tel: 022-62263303; email id: complianceofficer@sharekhan.com

For any complaints/grievance, email us at igc@sharekhan.com or you may even call Customer Service desk on - 022- 41523200/022-69920600.